Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > shocking we're going down, it makes no sense....
View:
Post by Humanist on Dec 05, 2022 9:56am

shocking we're going down, it makes no sense....

eom
Comment by SuperTrader1970 on Dec 05, 2022 10:05am
ATS bringing it down
Comment by Humanist on Dec 05, 2022 10:07am
ATS?????
Comment by Humanist on Dec 05, 2022 10:23am
no worries i know what you mean, lol i always refer to them as algos.... thx 
Comment by SuperTrader1970 on Dec 05, 2022 10:30am
Whos is the Turds dumping this? -24.32% Dumb
Comment by SuperTrader1970 on Dec 07, 2022 3:10pm
Lets go!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities